Improvement of glucose levels into the normal range can occur in some people living with
diabetes, either spontaneously or after medical interventions, and in some cases can persist …

Diabetic kidney disease is the leading cause of kidney failure worldwide; in the USA, it
accounts for over 50% of individuals entering dialysis or transplant programmes. Unlike …

The management of type 2 diabetes mellitus (T2DM) is becoming increasingly complex.
Sodium–glucose cotransporter type 2 inhibitors (SGLT2is) are the newest antidiabetic …

Chronic exposure of glucose rich environment creates several physiological and
pathophysiological changes. There are several pathways by which hyperglycemia …

Oxidative stress is increased in metabolic syndrome and type 2 diabetes mellitus (T2DM)
and this appears to underlie the development of cardiovascular disease, T2DM and diabetic …

Background. Sodium-glucose cotransporter 2 (SGLT2) inhibitors lower glycemia by
enhancing urinary glucose excretion. The physiologic response to pharmacologically …

Abstract Thioredoxins (Trxs), glutaredoxins (Grxs), and peroxiredoxins (Prxs) have been
characterized as electron donors, guards of the intracellular redox state, and “antioxidants” …

OBJECTIVE—To estimate the prevalence of and the cardiovascular risk associated with the
metabolic syndrome using the new definition proposed by the World Health Organization …

Type 2 diabetes mellitus has become an epidemic, and virtually no physician is without
patients who have the disease. Whereas insulin insensitivity is an early phenomenon partly …

The relative contributions of insulin resistance and beta-cell dysfunction to the
pathophysiology of Type 2 diabetes have been debated extensively. The concept that a …